ArticleFrontiers in public health2025
Comparative analysis of liver cancer burden trends in China and worldwide between 1990 and 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- tRNA‑derived RNAs in hepatic diseases: From biological functions to clinical translation (Review).International journal of molecular medicine · 2026Review
- Research on a rapid and accurate diagnosis platform for liver fibrosis based on machine learning-assisted SERS technology.Biomedical optics express · 2026Article
- Hepatocellular carcinoma and vitamin D metabolism: novel targets and therapeutic strategies.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- The global burden and trends of cutaneous leishmaniasis from 1990 to 2021 with projections to 2036: a population-based study.Journal of health, population, and nutrition · 2026Article
- Trends in liver cancer burden in China and G20: a comparative analysis using GBD 2021.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides comprehensive data on liver cancer burden worldwide. This study aims to analyze and compare the trends in liver cancer burden in China and globally between 1990 and 2021. Methods: Data were extracted from the GBD 2021 database, which includes incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for liver cancer in 204 countries and territories. Age-standardized rates (ASIR, ASPR, ASMR, ASDR) and crude rates (CIR, CPR, CMR, CDR) were calculated. Joinpoint regression analysis was used to determine the average annual percentage change (AAPC) in liver cancer burden trends. Results: In China, the number of liver cancer cases increased from 96,434 in 1990 to 196,637 in 2021, while the age-standardized incidence rate (ASIR) decreased. Globally, cases increased from 244,689 to 529,202, with a slight increase in ASIR. The age-standardized prevalence rate (ASPR) in China remained stable, while globally it increased. Age-standardized mortality rates (ASMR) and age-standardized DALY rates (ASDR) decreased in both China and globally. Males had higher rates than females in all age groups. The peak age for liver cancer burden occurred earlier in Chinese males compared to the global average. Conclusion: The liver cancer burden in China has declined over the past three decades, with a more significant decrease in China than globally. However, China still faces a higher burden compared to the global average. The earlier peak in liver cancer burden among Chinese males suggests the need for targeted prevention and control measures, especially in light of the impact of risk factors like hepatitis B and C, alcohol consumption, drug abuse, obesity, diabetes and tobacco use. Globally, liver cancer remains a significant public health challenge with rising incidence and prevalence rates, emphasizing the need for a comprehensive global approach to liver cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.